Navigation Links
Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
Date:5/5/2009

REDWOOD CITY, Calif., May 5 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced a multi-year agreement with AstraZeneca. AstraZeneca plans to expand the utilization of IPA in its research and target discovery programs to gain deeper domain knowledge of disease-related pathways and targets.

As part of the agreement, AstraZeneca researchers plan to leverage the powerful analysis application, to build biological models, analyze data, and reliably answer sophisticated biological and chemical questions in their effort to identify and progress promising targets.

Results generated in IPA can be easily shared across teams, so researchers can work together to make more informed decisions. "IPA is an extensive platform for understanding and communicating the dynamic behaviors of complex biological systems," said Dr Ian Dix, Principal Informatics Scientist, AstraZeneca. "IPA can support a wide range of research objectives across our target and biomarker discovery programs - such as providing insight into target efficacy, drugability and, increasingly, toxicity. The richness and contextual nature of the content is important for us because it provides a detailed view of the molecular basis of disease, critical in the drug discovery decision-making process."

"We are pleased to enhance and extend our relationship with AstraZeneca and to continue to provide AstraZeneca's researchers with greater workflow and decision support," said Sean Scott, SVP of Sales and Operations at Ingenuity Systems. "IPA continues to deliver value to AstraZeneca researchers by providing the right capabilities and content to understand biological systems and uncover insights that impact business decisions."

About Ingenuity Pathways Analysis

Ingenuity Pathways Analysis (IPA) is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA's search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals.

About Ingenuity Systems(R)

Ingenuity Systems is a leading provider of information solutions and custom services for life science researchers, computational biologists and bioinformaticists, and life science industry suppliers. Our long-term focus on innovation in semantic search has allowed us to create groundbreaking technologies that have one common goal -- to generate maximum value from all types of biological and chemical knowledge. Ingenuity offerings leverage the Ingenuity Knowledge Base, which contains uniquely structured literature findings that allow scientists to ask complex biological questions and gain rapid insight into their experimental data or systems of interest. Today, Ingenuity's solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, academic, and government research institutions worldwide. For more information visit: www.ingenuity.com

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information visit: www.astrazeneca.com


'/>"/>
SOURCE Ingenuity Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ingenuity Systems and CHDI Announce Multi-Year Deal for Disease-Specific Knowledge Platform
2. Ingenuitys Path Designer is Selected as Best New Product by Life Science Community at 2008 Molecular Medicine Conference
3. Ingenuity Systems Delivers Key Milestones in FDA Collaboration to Facilitate Genomic Data Review
4. Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008
5. Neogen Acquires International Diagnostic Systems
6. Healthcare Management Systems Celebrates 25 Years
7. Electronic prescribing systems boost efficiency, may lead to improved quality of care
8. Solta Medical Receives Regulatory Approval to Market Thermage Systems in China
9. Dynasplint Systems, Inc. Launches Two New Web Sites Plus Social Media Tools
10. IRIDEX Announces Shipment of New IQ 577(TM) Laser Systems
11. Sanuvox UV Air Sterilization Systems Ability to Destroy Airborne Type A Influenza including Swine Flu (H1N1)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: